Posttransplantation cyclophosphamide (PTCy) recently has had a marked impact on human allogeneic hematopoietic cell transplantation (HCT). Yet our understanding of how PTCy prevents graft-versus-host disease (GVHD) largely has been extrapolated from MHCmatched murine skin-allografting models that were highly contextual in their efficacy. Herein, we developed a T cell-replete, MHC-haploidentical, murine HCT model (B6C3F1®B6D2F1) to test the putative underlying mechanisms: alloreactive T cell elimination, alloreactive T cell intrathymic clonal deletion, and suppressor T cell induction. In this model and as confirmed in four others, PTCy did not eliminate alloreactive T cells identified using either specific Vbs or the 2C or 4C T cell receptors. Furthermore, the thymus was not necessary for PTCy's efficacy. Rather, PTCy induced alloreactive T cell functional impairment, which was supported by highly active suppressive mechanisms established within one day after PTCy that were sufficient to prevent new donor T cells from causing GVHD. These suppressive mechanisms included the rapid, preferential recovery of CD4 + CD25 + Foxp3 + regulatory T cells, including those that were alloantigen specific, which served an increasingly critical function over time. Our results prompt a paradigm shift in our mechanistic understanding of PTCy. These results have direct clinical implications for understanding tolerance induction and for rationally developing novel strategies to improve patient outcomes.
Introduction
Although potentially curative for many otherwise incurable hematologic malignancies, allogeneic hematopoietic cell transplantation (HCT) historically was inaccessible to many patients for lack of HLA-matched donors (1, 2) . Nearly all patients have HLAhaploidentical donors, but early results of HLA-haploidentical HCT showed high mortality due to prohibitive rates of severe graft-versus-host disease (GVHD) (2, 3) .
Novel clinical approaches, including posttransplantation cyclophosphamide (PTCy), now safely facilitate HLA-haploidentical HCT (2) . It is standard for PTCy to be given at 50 mg/kg/d on days +3 and +4 and to be used alone or in combination with other GVHD prophylactic agents depending on the characteristics, including donor type, of the HCT platform (2) . Regardless of the platform, PTCy prevents both severe acute and chronic GVHD (2) , minimizes the need for other immunosuppression (4, 5) , and preserves infectious immunity (2, (6) (7) (8) (9) , ultimately resulting in low rates of nonrelapse mortality. Since malignancy recurrence rates appear similar to those with standard HCT (4, 10) , recent registry studies suggest that HLA-haploidentical HCT with PTCy results in similar survival, but lower chronic GVHD rates, compared with HLA-matched HCT using standard GVHD prophylaxis (11) (12) (13) . Long-term outcomes are not yet known, but PTCy does not appear to be associated with increased rates of late toxicities, such as secondary malignancies (14) . Furthermore, PTCy is relatively inexpensive and its administration requires little specialized expertise or infrastructure. Consequently, PTCy-based HLA-haploidentical HCT is rapidly increasing worldwide.
Yet limited mechanistic data in HCT models existed prior to PTCy's successful clinical translation (15) . PTCy was most fully developed preclinically in MHC-matched murine skin-allografting models, where, combined with donor splenocyte infusion 2 to 3 days beforehand, PTCy effectively prevented rejection of subsequently placed skin allografts (16, 17) . Exploiting strain-specific differential expression of certain T cell receptor (TCR) Vβs as markers of alloreactive cells (18) , these studies found a marked decrease in alloreactive CD4 + , but not CD8 + , T cells in PTCy-treated mice (19, 20) . Thus, PTCy was believed to work via selective alloreactive T cell elimination, thought to occur primarily through direct destruction of alloreactive T cells proliferating at the time of PTCy and secondarily via intrathymic clonal deletion of alloreactive T cell precursors (19) (20) (21) (22) . Suppressor T cells were shown to play an adjunct role in maintaining tolerance, although there was discrepancy regarding whether these were CD4 + or CD8 + (20, 23, 24) . The relevance of these findings to HCT remains unclear. PTCy's effectiveness in skin-allografting models was highly contextual, requiring specific MHC-matching, type and dose of donor Posttransplantation cyclophosphamide (PTCy) recently has had a marked impact on human allogeneic hematopoietic cell transplantation (HCT). Yet our understanding of how PTCy prevents graft-versus-host disease (GVHD) largely has been extrapolated from MHC-matched murine skin-allografting models that were highly contextual in their efficacy. Herein, we developed a T cell-replete, MHC-haploidentical, murine HCT model (B6C3F1→B6D2F1) to test the putative underlying mechanisms: alloreactive T cell elimination, alloreactive T cell intrathymic clonal deletion, and suppressor T cell induction. In this model and as confirmed in four others, PTCy did not eliminate alloreactive T cells identified using either specific Vβs or the 2C or 4C T cell receptors. Furthermore, the thymus was not necessary for PTCy's efficacy. Rather, PTCy induced alloreactive T cell functional impairment, which was supported by highly active suppressive mechanisms established within one day after PTCy that were sufficient to prevent new donor T cells from causing GVHD. These suppressive mechanisms included the rapid, preferential recovery of CD4 + CD25 +
Foxp3
+ regulatory T cells, including those that were alloantigen specific, which served an increasingly critical function over time. Our results prompt a paradigm shift in our mechanistic understanding of PTCy. These results have direct clinical implications for understanding tolerance induction and for rationally developing novel strategies to improve patient outcomes.
Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression Lucas P. Wachsmuth, 1 Michael T. Patterson, 1 Michael A. Eckhaus, 2 David J. Venzon, 3 Ronald E. Gress, 1 and Christopher G. Kanakry Table 1 ) at days +7 and +21 showed that mice treated with 25 mg/kg/d PTCy had minimal to mild GVHD, which was significantly less severe than that observed in mice treated with vehicle or with ineffectively low (5 mg/kg/d) or high (100 mg/kg/d) PTCy doses ( Figure 1 , E and F, and Supplemental Table 2 ). Mice treated with 25 mg/kg PTCy had a characteristic and reproducible loss in weight occurring between days +50 and +90 that was dramatic but transient for a given mouse ( Figure 1A and Supplemental Figure 4 ) and was accompanied by worsening clinical scores during this period. Histopathologic assessment (n = 10) at day +50 showed focal proliferative and ulcerative intestinal lesions in half of the mice (Supplemental Figure 4) , which may account for these clinical changes. Yet mice nearly always recovered, steadily gaining weight and normalizing their clinical scores after days +90-100. This phenomenon was not observed or was observed only to a limited extent in mice treated with TCD BM and PTCy without splenocytes (Supplemental Figure 5) . Mice treated with 100 mg/kg PTCy had significantly worse GVHD histopathologically at day +21 compared with mice treated with 25 mg/kg PTCy ( Figure 1F ), but drug toxicity appeared to be a major contributing cause of late morbidity and mortality after the higher dose (Supplemental Figure 3) . At day +200, surviving mice treated with PTCy, regardless of dose, had no histopathologic evidence of cutaneous, hepatic, gastrointestinal, or pulmonary GVHD.
Optimally dosed PTCy does not induce pan-T cell depletion, and even high-dose PTCy leads to immune reconstitution markedly distinct from TCD HCT. Some have asserted that PTCy works via in vivo T cell depletion. Total numbers of T cells recovered from blood, peripheral lymph nodes, spleen, and liver at day +7 were lower in 25 mg/kg PTCy-treated mice than in vehicle-treated mice, but were in the same log range (Figure 2A ). In fact, the numbers of T cells infiltrating the liver, a GVHD target organ, were higher in mice treated with allogeneic splenocytes and 25 mg/kg PTCy than in syngeneic controls. 100 mg/kg PTCy did result in broad reductions in T cell numbers at day +7, but T cell numbers greatly rebounded by day +21 ( Figure 2B ). Furthermore, the composition of recovering leukocyte subsets in mice treated with 100 mg/kg PTCy remained markedly dissimilar from that in mice treated with TCD BM alone, but rather similar to that in mice treated with splenocytes and either vehicle or lower PTCy doses (Supplemental Figure 6 ). Thus, any T cell-depleting effect of the highest PTCy dose appears immunologically distinct from that with ex vivo TCD.
Optimally dosed PTCy significantly reduces CD4 + but not CD8 + T cell proliferation. PTCy is thought to preferentially kill proliferating T cells, contributing to its putative role in alloreactive T cell elimination (38) . High proliferation (Ki-67 + ) rates were seen at day +7 in both CD4 + and CD8 + T cell subsets of vehicle-treated mice ( Figure 2C ), consistent with high T cell proliferation (Ki-67 + ) rates observed early after transplant in humans treated with HLA-haploidentical HCT (36, 37) . With increasing PTCy doses in our model, decreasing CD4 + T cell proliferation was seen. However, 25 mg/kg PTCy did not significantly reduce CD8 + T cell proliferation in nonblood tissue compartments; only with 100 mg/kg PTCy, a cells, PTCy dose, and recipient age (25) (26) (27) . Indeed, PTCy failed to prevent rejection of MHC-mismatched skin allografts without multiple rounds of PTCy or combination with T cell-depleting antibodies (16, 28) . These findings are at odds with the broad effectiveness of PTCy in human HCT across a wide range of recipient ages and donor graft types, cell doses, and HLA matching (2, 5, 29) .
Moreover, there is a fundamental disconnect between the mechanisms described in murine skin-allografting models and clinical observations in human HCT. Rates of grade II (clinically significant but not severe) acute GVHD after PTCy-based HCT are 30%-80% (2, 5, (30) (31) (32) , indicating that alloreactive T cell elimination is not achieved in these patients. Even so, only approximately 10%-20% of patients develop chronic GVHD (2, 5, (30) (31) (32) , indicating no ongoing clinical alloreactivity despite alloreactive T cell persistence. This disconnect led us to consider the mechanistic importance of CD4 + Tregs in PTCy-mediated GVHD prevention, revealing that Tregs were resistant to PTCy in HLA-mismatched mixed lymphocyte cultures (33) , recovered rapidly after HCT in humans (33) , and were necessary immediately after transplant for GVHD prevention by PTCy in xenogeneic (33) and MHC-matched (34) murine HCT models. Other groups have reported that PTCy preferentially targets T cells undergoing antigen-driven rather than lymphopenia-driven proliferation in MHC-matched murine HCT (35) and that T cells of a stem cell-memory phenotype dominate early immune reconstitution after HLA-haploidentical HCT (36, 37) . Yet the accepted paradigm of how PTCy prevents GVHD in HCT is still largely extrapolated from the murine MHC-matched skin-allografting studies (38) .
To better understand the biology of tolerance induction and specifically how PTCy prevents GVHD in order to rationally improve clinical outcomes, we developed an MHC-haploidentical HCT model that directly parallels human HLA-haploidentical HCT. We used this model to probe the central tenets of the existing paradigm (38) , specifically testing the hypothesis that selective elimination of alloreactive T cells is a central and necessary mechanism of PTCy-mediated GVHD prevention after HCT. PTCy was administered on days +3 and +4 to parallel clinical practice (2) . PTCy doses between 10 and 50 mg/kg/d effectively prevented fatal GVHD, with 25 mg/kg/d being the optimal tested dose in this model ( Figure 1A experiments are shown. n = 10/group for A and B; n = 6/group for C and E; and n = 8/group for D and F except for the 100 mg/kg PTCy groups in D (n = 5) and F (n = 7). ***P ≤ 0.001; ****P ≤ 0.0001, 1-way ANOVA followed by the Holm-Šidák post hoc test. Figure 10 ) (15) , demonstrating that selective alloreactive T cell elimination is not a necessary mechanism underlying PTCy-mediated GVHD prophylaxis.
Results

PTCy effectively controls GVHD in a T cell-replete, MHC-haploidentical HCT model (B6C3F1→B6D2F1)
.
1A and Supplemental
Alloreactive In the alloreactive setting (B6D2F1 recipients), 2C TCR + T cells were highly proliferative at days +3 and +7, and PTCy did not reduce this proliferation (Figure 3, A and B) . Rather, despite PTCy on days +3 and +4, 2C TCR + T cell percentages actually increased from day +3 to comprise 35%-80% of CD8 + T cells on day +7 (Figure 3B ). 2C TCR + T cells persisted at day +200 and remained highly proliferative ( Figure 3C ). These results further disprove that alloreactive T cell elimination is necessary for GVHD prevention by PTCy and reveal that alloreactive T cell clonal expansion can occur despite PTCy.
To explore the fate of nonalloreactive T cells after PTCy, we used the B6→B6C3F1 MHC-haploidentical model and manufactured analogous grafts in which approximately 8% of infused CD8 + T cells were 2C TCR + . 2C TCR + T cells, nonalloreactive in this model, maintained low proliferation and a naive phenotype, and consequently contracted by day +7 irrespective of PTCy administration ( Figure 3, D-F 
Foxp3
-T cells were not eliminated, but rather were found at similar or even significantly higher percentages in PTCy-treated compared with vehicle-treated mice ( Figure 4B ). These results further confirm that alloreactive T cells, regardless of their specificity or identity as CD4 + or CD8 + , are not eliminated by PTCy, but rather appear to persist near to or even above percentages observed in mice not treated with PTCy.
Intrathymic clonal deletion is not necessary for GVHD prevention by PTCy. The second of the 3 mechanisms previously proposed to be responsible for PTCy-mediated GVHD prevention is intrathymic clonal deletion of alloreactive T cell precursors (20) (21) (22) 38) . We tested this hypothesis by using thymectomized recipients in our B6C3F1→B6D2F1 model. PTCy (25 mg/kg) remained highgenome (18 
-donor T cells were not eliminated at day +7 by PTCy ( Figure 2D ), but rather persisted at percentages similar to those seen in donors (Supplemental Figure 7 ). This persistence was seen regardless of PTCy dose; indeed, Vβ6 + percentages of CD4 + T cells actually were significantly increased in the spleen and liver of mice treated with 100 mg/kg PTCy ( Figure 2D ). The persistence of Vβ6 + T cells near or above percentages seen in donors continued at days +21 and +200 ( 
-and Vβ6 + CD8 + T cell numbers substantially rebounded by day +21 to levels found in vehicletreated mice (Supplemental Figure 8 , C and D), potentially contributing to the worse GVHD observed histopathologically at that time point in mice treated with 100 mg/kg PTCy ( Figure 1F ).
Persistence of alloreactive Vβ6 + T cells after PTCy also was seen in other murine HCT models, including another MHC-haploidentical (B6→B6D2F1; day +7), an MHC-disparate (C3H→B6D2F1; days +6 and +200), and an MHC-matched (C3H→AKR; day +7) model (Supplemental Figure 9 , Supplemental Figure 10 , and Supplemental Figure 11 ). Furthermore, persistence of alloreactive Vβ3 and Vβ5 TCR + T cells after PTCy was observed at day +7 in a B6→B6C3F1 MHC-haploidentical model (Supplemental Figure 12) . In some models, the percentages of alloreactive T cells were reduced by PTCy compared with those in vehicle-treated mice, but this appeared related to curbing preferential expansion of alloreactive T cells, as the percentages remained near or frequently above donor percentages. Nevertheless, severe GVHD was abated by PTCy in these models ( Figure   Figure 
Optimally dosed PTCy neither induces pan-T cell depletion nor eliminates alloreactive T cells, but does reduce CD4
+ T cell proliferation. Mice were transplanted as in Figure 1 and assessed at day +7, +21, or +200. All groups were allogeneic (Allo, B6C3F1→B6D2F1) unless specifically labeled as syngeneic (B6D2F1→B6D2F1 10 .5%) and even exceeded donor levels in the spleen and liver at day +7 after 100 mg/kg PTCy. These effects contrast with those in mice treated with TCD BM without PTCy in which Vβ6 + T cells were deleted over time. Combined results from (A, C, D) 3 (n = 6/group) or (B, E) 2 (n = 8/group except 100 mg/kg PTCy [n = 5]) independent experiments are shown. F shows data from all mice from Figure 1A surviving to day +200. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001, 1-way ANOVA followed by the Holm-Šidák post hoc test using the vehicle-treated splenocyte group as the control. LN, peripheral lymph nodes. jci.org Volume 129 Number 6 June 2019 ly effective; indeed, outcomes were superimposable with results using nonthymectomized recipients ( Figure 5 ), negating a necessary role for the thymus in PTCy-mediated GVHD prevention. Alloreactive T cells become functionally impaired, but not anergic, after PTCy. Despite alloreactive T cells persisting and even expanding after 25 mg/kg PTCy, heavily infiltrating a GVHD target organ, and remaining highly proliferative ( Figure 2 , C-F, Figure 3 , B and C, and Figure 6A ), minimal histopathologic evidence of GVHD was observed and GVHD-related mortality was abated ( Figure 1 , A, E, and F). To further test the functional ability of PTCy-treated alloreactive T cells, using our WT B6C3F1→B6D2F1 model, we isolated liver-infiltrating T cells at day +21 and restimulated them in vitro. Donor T cells from PTCy-treated mice had minimal proliferation in response to self (donor parental) antigen, but proliferated robustly upon reexposure to allogeneic (host parental or third-party H2k d+ strain) antigen ( Figure 6 , B and C, and Supplemental Figure 13 ). Even so, proliferation of CD8 + T cells and production of both Th1 and Th2 cytokines were significantly reduced compared with that in vehicle-treated mice ( 
Foxp3
-T cells (Supplemental Figure 8) . This relative imbalance of conventional T cell versus Treg recovery may contribute to the worse GVHD seen histopathologically in the 100 mg/kg PTCy treatment group.
Using Vβ6 + as a marker of alloantigen-specific Tregs, we found that mice treated with 25 or 100 mg/kg PTCy had increased percentages of alloantigen-specific Tregs in the liver at both days +7 and +21 (Figure 8, D Figure  17) . Therefore, we employed a multipronged approach to maximally deplete Foxp3 + Tregs. Leveraging the presence of the Foxp3 gene on the X chromosome, male B6C3F1 Foxp3 diphtheria toxin (DT) receptor-expressing mice were used as donors to ensure all Foxp3 + cells would be susceptible to depletion. DT was adminis- Figure 2C. (B) Nevertheless, 4C TCR + CD4 + CD25 -Foxp3 -T cells persisted at day +7 at similar or even higher percentages compared with levels observed in vehicle-treated mice. Combined results from 2 independent experiments are shown using n = 8/group for each of the vehicle-treated and PTCy-treated groups. n = 6 for mice assessed on day +3. *P ≤ 0.05; ****P ≤ 0.0001, unpaired t test with Welch's correction for the mice treated with or without PTCy assessed on day +7. NE indicates that all samples in that subset were not evaluable due to the parent populations all being less than 100 cells. jci.org Volume 129 Number 6 June 2019
anisms for PTCy-mediated GVHD prevention by taking previously transplanted nonthymectomized mice and reinfusing them with 40 or 120 × 10 6 splenocytes from new PTCy-nonexposed donors at specific time points. Regardless of time point, mice initially transplanted with TCD BM without PTCy developed severe, frequently fatal GVHD after splenocyte reinfusion ( Figure 10 , A-C, and Supplemental Figure 21 ). Conversely, mice transplanted initially with TCD BM, splenocytes, and 25 mg/kg PTCy all survived and even steadily gained weight after reinfusion at 4 to 5 months after transplant ( Figure 10A and Supplemental Figure 21A ). Similar findings were seen in thymectomized mice (Supplemental Figure  21B) . We next assessed how early these suppressive mechanisms were induced. Mice transplanted with splenocytes and PTCy that received splenocyte reinfusion either on day +28 ( Figure 10B ) or even day +5 (24 hours after the last cyclophosphamide dose) (Figure 10C) did not develop GVHD and were indistinguishable from PTCy-treated mice reinfused with vehicle. Importantly, intraperitoneally administered cyclophosphamide has a short half-life of approximately 30 minutes in mice and is undetectable in the blood after 3 to 4 hours (45) . These data suggest that PTCy rapidly induces suppressive mechanisms that are sufficient to prevent GVHD induction by alloreactive T cells not exposed to cyclophosphamide.
Discussion
Our data conclusively show in 5 HCT models that alloreactive T cells are not eliminated after PTCy-based murine HCT regardless of PTCy dose, degree of MHC-matching, or specificity of alloreactive cell; indeed, alloreactive T cells remained near or frequently above donor percentages. Although not eliminated, CD4
+ alloreactive T cells had reduced proliferation shortly after PTCy and, consequently, their early expansion was constrained. Furthermore, CD4
+ and CD8 + alloreactive T cells became functionally impaired tered for 2 consecutive days at 25 μg/kg/d and then again 6 days later for 2 more consecutive days to overcome the Treg rebound seen approximately 7 days after depletion using this system (42) . Thymectomized recipients were used to nullify any potential confounding effect of new Treg maturation in the thymus. This approach provided a greater than 2-log CD4 + Foxp3 + depletion to less than 0.1% of CD4 + splenocytes on day +10. Foxp3 + depletion immediately after transplant in PTCy-treated mice resulted in severe GVHD clinically and histopathologically that was fatal in a subset of mice and was only partially attenuated with eventual recovery of Tregs to normal levels ( Figure 9A, Supplemental Figure 18 , and Supplemental Figure 19 ).
It is unknown whether Tregs are only critical for PTCymediated GVHD prevention immediately after transplant (33, 34) or whether their continued presence is necessary to maintain tolerance. Selective depletion of Foxp3 + T cells at defined posttransplant time points (day +30, +60, or +150) also resulted in severe GVHD clinically and histopathologically ( Figure 9 , B and C, Supplemental Figure 18 , and Supplemental Figure 19 ). In fact, the rapidity, severity, and lethality of the induced GVHD were more pronounced when Tregs were depleted at later time points. CD4 + Tregs given 4 days prior to conventional T cells can effectively prevent GVHD for MHC-matched murine HCT or (at high Treg/effector T cell ratios) TCD HLA-haploidentical HCT (43, 44) . However, in our B6C3F1→B6D2F1 model, severe and fatal GVHD still resulted when CD4 + Tregs were given at physiologic or supraphysiologic doses 4 days prior to T cell-replete transplant (Supplemental Figure 20) , suggesting that Foxp3 + Tregs, while necessary, are not sufficient to prevent severe GVHD in T cell-replete MHC-haploidentical HCT.
Highly active suppressive mechanisms are induced immediately after PTCy. We further tested the importance of suppressive mech- The procedures in B-D were repeated at day +150. PTCy-treated T cells continued to proliferate and produce IFN-γ and IL-2 in response to alloantigen but not self-antigen; these differences were not due to disparities in the CD4 + CD25 + Foxp3 + T cell content of the restimulated cells (P = 0.21; not shown). Combined results from 2 independent experiments are shown for all parts. n = 8 mice/group for all parts except the 100 mg/kg PTCy group shown in the left panel in A (n = 5), the right panel in A (which shows all mice from Figure 1A surviving to day 200), E-F (n = 5-6/group), and the 25 mg/kg PTCy groups in G (n = 7). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001, unpaired t test with Welch's correction. ND, not detectable. Statistical testing of cytokines was adjusted for multiple comparisons by the Holm-Šidák method. jci.org Volume 129 Number 6 June 2019 eliminated by PTCy in patients and can mediate clinically significant GVHD and/or graft-versus-tumor immunity. Furthermore, in skin-allografting models, tolerance was maintained even if intrathymic clonal deletion broke down at later stages (20) , challenging the necessity of the thymus for PTCy-mediated GVHD prevention. Indeed, in human HCT, PTCy remains effective in older adults and/or those treated with myeloablative conditioning in whom residual thymic function may be limited or absent (2, 29) The current model (38) for understanding how PTCy prevents GVHD largely was extrapolated from skin-allografting models that were highly contextual in their efficacy (25) (26) (27) . Using an identical dose (200 mg/kg) and timing (day +3) of PTCy in the same C3H/AKR MHC-matched model, we did show a reduction in Vβ6 + T cell percentages compared with those in vehicle-treated mice, and this reduction was more pronounced with higher PTCy doses (Supplemental Figure 11) ; however, the percentages remained near or above donor levels. Differences in these results may reflect a difference in graft-versus-host compared with host-versus-graft immunity, peculiarities of mixed chimeric states, and/or insufficient splenocyte dose; 100 × 10 6 splenocytes were required in the skin-allografting models to successfully induce tolerance, and lower cell doses could lead to accelerated rejection (25, 26) . The use of radiation is unlikely to be a contributing factor, as we actually observed increased Vβ6 + T cell percentages after PTCy in nonirradiated mice in our B6→B6D2F1 model (Supplemental Figure 9) . Importantly, alloreactive T cell clonal deletion can occur through peripheral tolerance mechanisms independent of PTCy, as demonstrated in thymectomized recipients of TCD BM not treated with PTCy in which the percentages of both CD4 +
Vβ6
+ and CD8 + Vβ6 + T cells were significantly reduced (Supplemental Figure 19) . Thus, alloreactive T cell depletion seen in specific contexts in skinallografting models does not necessarily imply direct elimination by PTCy. Indeed, the depletion seen in those mixed chimeric models occurred progressively over several weeks, and the percentages in terms of their ability to cause clinical GVHD and to proliferate and elaborate inflammatory cytokines in vitro in response to alloantigen restimulation. This functional impairment is at least partially reversible, as Foxp3 + depletion resulted in severe clinical and histopathologic GVHD, consistent with our prior studies (33, 34 ). Yet our current work revealed additional insights showing that the necessary role of Foxp3 + Tregs in restraining alloreactive T cells surviving PTCy is increasingly critical over time and that alloantigen-specific Tregs preferentially persist after PTCy. Moreover, we found that suppressive mechanisms are induced immediately after PTCy and are sufficient to control PTCy-nonexposed alloreactive T cells infused as early as day +5.
Further study is needed to determine to what extent our mechanistic findings are conserved in human HCT using PTCy. This is particularly true given that our murine models rely on splenocytes as the source of T cells to initiate GVHD, which is distinct from human HCT where T cell-replete BM or peripheral blood are the source of T cells. Furthermore, PTCy is often used clinically in combination with other immunosuppressants (2), particularly in the HLA-haploidentical HCT setting, and these other immunosuppressants can interact with PTCy in terms of the effects on immune subset survival and reconstitution (33, 46) . Even so, given that PTCy remains effective at preventing chronic GVHD when used alone or in combination with other immunosuppressants (2, 46) , it is likely that the effects of PTCy itself are dominant and not blocked by the integration of these other agents.
Importantly, supporting the possible direct clinical relevance of our findings, our results appear fully consistent with clinical outcomes. In human HCT, grade II acute GVHD frequently occurs after PTCy (2, 5, (30) (31) (32) and even may be associated with better malignancy control (5, 47) . Furthermore, high rates of severe acute GVHD are seen when PTCy is used as single-agent GVHD prophylaxis after peripheral blood HLA-matched HCT (48, 49) . These findings strongly support that alloreactive T cells are not by PTCy may cause GVHD. This effect may be exacerbated in the setting of lower Treg levels (Supplemental Figure 18 ) or when Tregs are removed ( Figure 9 ) (33, 34) , confirming that Tregs after PTCy retain functional suppressive capability in vivo. The Tregs surviving and reconstituting after PTCy in this and our prior studies appear to be chiefly natural Tregs, and in our prior studies, we showed that they also retain suppressive function in vitro (33, 34) . Alloreactivity persisting despite PTCy generally is controlled prior to progression to severe acute GVHD, which may be associated with a compensatory increase in Tregs in PTCy-treated patients (33) . The necessary role for Tregs that is increasingly important over time after transplant in our B6C3F1→B6D2F1 model may explain clinical chronic GVHD prevention by PTCy; this hypothesis is supported by the amelioration of clinical chronic GVHD manifestations with Treg expansion by IL-2 (52). Although the contribution of CD8 + Foxp3 + Tregs (53, 54) to PTCy-mediated were reduced only in half at 2 weeks after PTCy (21), suggesting that the observed effect was not solely a result of immediate killing by PTCy. Furthermore, PTCy did not eliminate alloreactive T cells in MHC-mismatched skin-allografting models (21), consistent with our data. Moreover, donor T cells continue to proliferate, although to a lower degree, despite PTCy treatment after MHCmatched HCT (35) , which is also consistent with our results. Overall, even if alloreactive T cell depletion may occur after PTCy in very specific contexts, this depletion absolutely is not required for PTCy to effectively prevent severe GVHD, as shown in our several HCT models, consistent with recent findings of the persistence of self-reactive T cells in autologous tolerant states (50, 51) . Our data support a 2-part mechanism of GVHD attenuation by PTCy involving direct effects both on alloreactive T cells themselves and on suppressive cell populations that control GVHD. T cells whose functional alloreactivity is inadequately restrained Of note, all samples in the day +7 100 mg/kg PTCy group had Treg numbers of less than 100 cells and would therefore normally be excluded, but are included here for illustrative purposes. Combined results from (A, D) 3 (n = 6/group) or (B, E) 2 (n = 8/group except 100 mg/kg PTCy; n = 5) independent experiments are shown. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001, 1-way ANOVA with Holm-Šidák post hoc test using the allogeneic (Allo) TCD BM and splenocyte, vehicle group (labeled Allo, vehicle for A, D and BM, splen, vehicle for B, E) as control. jci.org Volume 129 Number 6 June 2019 tory. T cell dysfunction can occur via several mechanisms, including tolerance, anergy, ignorance, senescence, and exhaustion (55) . We have shown that central or peripheral deletional tolerance does not occur after PTCy in our models. Peripheral tolerance can occur through active suppression by Tregs, which we have shown to play a role. However, 2C TCR + T cells removed from the suppressive environment retained functional impairment in vivo ( Figure 7 ) and alloreactive T cells in Treg-depleted mixed lymphocyte cultures retained deficits in proliferation and inflammatory cytokine production (Figure 6 ), suggesting this is not the only operating mechanism. We have shown that PTCy-treated allore-GVHD prevention is unknown and these cells would be eliminated with Foxp3 depletion in our studies (34) , CD8 +
Foxp3
+ T cells were a minor population and their levels did not correlate with clinical outcome or treatment in our model (Supplemental Figure 18 and Supplemental Figure 22) . Furthermore, our prior data have suggested a dominant role for CD4 + Tregs (33, 34) . Overall, the exact nature of the alloreactive T cell functional impairment induced by PTCy and the operating mechanisms of regulation mediated by CD4 + Tregs and perhaps other suppressive populations in preventing or controlling GVHD after PTCy require further study and are ongoing areas of investigation in our labora- Figure 9 . Foxp3 + depletion induces severe and fatal GVHD, particularly at later posttransplant time points. DT treatment of thymectomized B6D2F1 mice transplanted with Foxp3-DTR-expressing B6C3F1 grafts from 9-to 13-week-old male donors beginning (A) immediately after transplant (days 0, +1, +6, +7), (B) at day +30 (days +30, +31, +36, +37) or day +60 (days +60, +61, +66, +67), or (C) at day +150 (days +150, +151, +156, +157) induced severe and frequently fatal GVHD. Survival was compared using the exact log-rank test. AUCs were compared using Wilcoxon's rank sum test. P values for B reflect comparisons of vehicle with DT day +30 (over days +30 to +150) or day +60 (over days +60 to +150), respectively. Weights and clinical scores in C were compared between the 2 DTR groups over days +150 to +250. Combined results from (A-B) 2 or (C) 4 independent experiments are shown. n = 10-16/group for A; n = 9-10/DTR group and n = 8/WT group for B; and n = 15, 9, and 12/group for the WT, DTR/vehicle, and DTR/DT groups, respectively, for C. jci.org Volume 129 Number 6 June 2019 Figure 10 . PTCy rapidly induces suppressive mechanisms that prevent new splenocytes not exposed to PTCy from causing GVHD. Recipient B6D2F1 mice were transplanted as in Figure 1 and received vehicle or PTCy on days +3 and +4. On day (A) +126, (B) +28, or (C) +5, all groups were reinfused with vehicle or with 40 × 10 6 or 120 × 10 6 splenocytes from new 10-to 12-week-old B6C3F1 donor mice. A shows the original treatments for each group, and all were reinfused with 120 × 10 6 splenocytes. Survival was compared using the exact log-rank test. Weight and clinical score AUCs were compared using Wilcoxon's rank sum test. AUC comparisons for B are over days +28 to +130, as the groups were identically treated prior to that time point. All other AUCs are over the entire evaluation period. P values show comparisons between the first and second groups (shown first) and the first and third groups (shown second). jci.org Volume 129 Number 6 June 2019
(Charles River) and B6.Cg-CD8a <a>Tg(Tcra2C,Tcrb2C)1Dlo female mice. B6.Cg-Tg(CD2-Tcra,Cd4-Tcrb)4CKang/Mmucd mice (40, 58) were obtained from the Mutant Mouse Resource and Research Center and were bred at the NCI, including the generation of B6C3F1 mice using C3H/HeNCrl male mice (Charles River Laboratories) and B6.Cg-Tg(CD2-Tcra,Cd4-Tcrb)4CKang/Mmucd female mice. For some experiments, thymectomy was performed by Charles River on B6D2F1 mice at 7 to 8 weeks of age. B6D2F1 mice were nonthymectomized except where specifically noted. All donors and recipients were 10-to 12-week-old female littermate controls except where otherwise specified. All mice were maintained in specific pathogen-free conditions at the NCI, where they were given food and water ad libitum.
HCT. Recipient mice were irradiated to 10.5 Gy in a single fraction using a Gammacell 40 Cesium-137 irradiator 6 to 8 hours prior to transplantation and were given levofloxacin-treated water (Akorn) from days 0 to +14. Grafts were resuspended in a total volume of 0.5 ml RPMI with l-glutamine and administered via tail vein injection. Based on dose titration experiments in the B6C3F1→B6D2F1 model (Supplemental Figure 1) and the desire to keep conditions similar across models, the cell dose for TCD BM was 10 × 10 6 and for RBC-depleted splenocytes was 40 × 10 6 cells except where otherwise specified. Mice were followed daily for survival and euthanized if deemed moribund by the veterinary staff. Blinded evaluations of clinical scores and weights were performed every 3 days according to a standardized scoring rubric (Supplemental Figure 23) , which was adapted from a previously published rubric (59) to the B6C3F1→B6D2F1 model. Graft preparation. Following euthanasia with CO 2 , spleens, tibias, and femurs were aseptically collected from donor mice. Spleens were mechanically disrupted over 70 μm nylon cell strainers using culture media (RPMI with l-glutamine, 10% fetal bovine serum, 1% sodium pyruvate, 1% MEM nonessential amino acids, 1% penicillin/ streptomycin, and 0.1% mercaptoethanol), RBC lysed twice using ACK Lysis Buffer, and refiltered over 70 μm cell strainers. BM was flushed from tibias and femurs using 26-gauge needles over 100 μm nylon cell strainers, resuspended at 20 × 10 6 cells/ml, and TCD using anti-Thy1.2 antibody (BioXCell) followed by treatment with guinea pig complement (CedarLane Drug preparation and administration. Cyclophosphamide (Baxter Oncology) was reconstituted in sterile PBS at 5 or 10 mg/ml, aliquoted, and cryopreserved at -80°C until the day of administration. At that time, an aliquot was thawed and diluted with sterile PBS to a concentration (depending on dose) that allowed for the administration of approximately 400-500 μl per mouse. DT (MilliporeSigma) was reconstituted at 2 mg/ml in sterile PBS, aliquoted, and cryopreserved active T cells proliferate in response to alloantigen in vivo and in vitro, traffic heavily to GVHD target organs, and do not assume an anergic phenotype, ruling out ignorance and making anergy or the functionally unresponsive form of peripheral tolerance less likely. GVHD prevention by PTCy is not blocked by calcineurin inhibitors (2), also arguing against anergy (56). PTCy's impact is early after transplant, before vehicle-treated mice die of GVHD, making senescence unlikely; senescence also tends to occur after repetitive, rather than excessive and continuous, antigen stimulation (57) . Excessive and continuous antigen exposure may lead to T cell exhaustion, which would fit with the functional defects we have observed. Therefore, our current operating hypothesis underlying ongoing work in the laboratory is that PTCy induces alloreactive T cell exhaustion, contributing to GVHD prevention.
Our findings provide fundamental insights that improve our understanding of how PTCy prevents GVHD. These new data should prompt a reevaluation of the currently accepted model and inspire further studies that will result in the development of a comprehensive new model grounded in experimental HCT data and consistent with clinical observations. Ultimately, this work may lay the foundation for the rational development of novel strategies that improve outcomes after PTCy-based HCT and are effective for the induction (or breaking) of tolerance in other clinical contexts.
Methods
Experimental design. The objective of this controlled laboratory study was to dissect the mechanistic basis for PTCy-mediated GVHD prevention. We specifically tested the hypotheses underlying the existing paradigm: 3 mechanisms are necessary for PTCy's efficacy: (a) selective elimination of alloreactive T cells, (b) intrathymic clonal deletion, and (c) induction of CD4 +
Foxp3
+ Tregs. Mice were randomized to each treatment group at the time of irradiation or, for DT depletion at day +150, at day +150. Evaluations of clinical scores and weights were performed in a blinded manner by the adjudicator being handed unlabeled cages from another investigator. Coded histopathologic slides were blindly scored by a veterinary pathologist using a standardized scoring rubric (Supplemental Table 1 ). GVHD experiments were performed with 5 mice/group/experiment and were repeated at least once. Flow cytometric and histopathologic studies within the first posttransplant month were designed using 6 to 8 total mice/group from 2 to 3 experiments. Flow cytometric studies at late posttransplant time points included all survivors of the original GVHD experiments. All data, including outliers, were included with one predetermined exception: flow cytometric cell-subset percentages were considered nonevaluable and excluded if the parent subset contained less than 100 events (i.e., the denominator was <100 DNA methylation analysis. Dry pellets of flow cytometrically sorted CD4 + T cell subsets were snap-frozen, stored at -80°C, and then shipped on dry ice to EpigenDx for DNA extraction, bisulfite modification, and pyrosequencing in triplicate of 4 CpG sites within intron 1 of the mouse Foxp3 TSDR (assay ID ADS568-FS2). Time points. For flow cytometric and histopathologic data, days +6 and +7 refer to the sixth and seventh days after transplant, respectively. Day +21 refers to days +20-22. Day +50 refers to days +49-50. Day +150 refers to days +145-158. Day +200 refers to days +200-210.
Statistics. Survival distributions were compared using the exact log-rank test. Point-wise weight comparisons and weight and clinical score AUC comparisons were performed using Wilcoxon's rank sum test. Point-wise clinical score comparisons were performed using the Cochrane-Armitage test for trend. Weight and clinical score data are shown as the mean ± SEM. Cell subset percentages were transformed using an Arcsin transformation prior to 1-way ANOVA or t test. Cell counts and cytokine values were natural logarithmically transformed prior to 1-way ANOVA or t test. Undetectable cytokine levels were assigned a value of 0.01 prior to transformation. Comparisons of cytokine levels in supernatant underwent the Holm-Šidák correction to account for multiple testing. ANOVAs, when significant, were followed with the Holm-Šidák post hoc test. The transformed data were used for statistical testing, but the nontransformed data are displayed for clarity of understanding and are shown as box-and-whisker plots. SAS/STAT (SAS), version 12, was used for analyses of survival, weight, and clinical score data. GraphPad Prism (GraphPad Software), version at -20°C until the day of administration. At that time, an aliquot was thawed and diluted with sterile PBS to a concentration of 1 μg/ml for injection. The same thawed vial was refrozen at -20°C for use for the next day's dosing. DT aliquots were never freeze-thawed more than 1 time. Cyclophosphamide or DT were administered intraperitoneally at approximately 24-hour intervals (e.g., day +3 means ~72 hours after transplant). Doses were based on the weight on the day of injection. Mice not receiving the drug were always given similar volumes of PBS vehicle intraperitoneally.
Histopathologic specimen preparation. Following CO 2 euthanasia, a section of left flank skin, 2 sections of liver, and 2 halves of the stomach were collected and placed in a 10% formalin solution (MilliporeSigma). The entirety of the intestines was intraluminally instilled with formalin and then placed in formalin in cassettes. For certain experiments, eyes, eyelids including conjunctiva, Harderian glands, and exorbital lacrimal glands were obtained, placed in cassettes, and fixed in formalin. For some experiments, lungs, heart, and kidneys also were collected. Lungs were intraluminally instilled with 2 to 3 ml of formalin via tracheal injection, placed whole along with the heart into a cassette, and placed in formalin. Kidneys were bisected in the coronal section and placed in cassettes in formalin. Complete autopsies were performed by veterinary pathologists and examined the skin, liver, stomach, small intestine, cecum, colon, lungs, heart, and kidneys as above, but also included the ovaries, uterus, brain, adrenal glands, spleen, thymus, and BM. All formalin-fixed tissue specimens were sent to Histoserv Inc. for paraffin embedding, slide preparation, and H&E staining.
Tissue processing for flow cytometric analysis. Mice were anesthetized using isoflurane and then terminally bled retroorbitally. Blood was collected via heparinized tubes into Eppendorf tubes containing 10 μl heparin (10,000 USP units per ml) and mixed immediately. Following blood collection, euthanasia of each animal was ensured using CO 2 . Spleens and peripheral (cervical, axillary, brachial, and inguinal) lymph nodes were collected. Livers were flushed of peripheral blood by cutting the portal vein and forcefully injecting 10 ml of sterile PBS into the heart, causing it to exsanguinate the liver. Spleens and lymph nodes were disrupted over 70 μm nylon cell strainers. Blood was RBC lysed twice, and spleens were RBC-lysed once using ACK lysis buffer. Livers were mechanically disrupted over 100 μm nylon cell strainers, RBC lysed, and subjected to density gradient centrifugation with 36% Percoll (GE Healthcare).
Flow cytometry. Up to 3 × 10 6 viable cells/sample were stained sequentially with the LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Thermo Fisher), extracellular antibodies, fixation/permeabilization (eBioscience Foxp3 Staining Kit), and intracellular antibodies. Single stains were prepared to generate compensations, and fluorescence-minus-one controls were prepared for specific markers (e.g., CD25 and Ki-67). Flow cytometric analysis examining leukocytes other than T cells also were treated with Mouse FC Block (BD Biosciences, clone 2.4G2) prior to extracellular antibody staining. Data were acquired on BD Fortessa or BD LSR II flow cytometers and analyzed using FACSDiva 8.0.1. Flow cytometric cell sorting was performed on a BD Influx. Fluorochrome-conjugated monoclonal antibodies used for flow cytometry included PerCP-Cy5.5 anti-B220 (clone RA3-6B2), APC-efluor780 anti-CD4 (clone GK1.5), efluor450 and APC antiFoxp3 (clone FJK-16S), PE-Cy7 anti-H2k b (clone AF6-88.5.5.3), and
